Catalog No.
Product Name
Application
Product Information
Citations
-
Potassium Channel Inhibitor
DPO-1 is a selective inhibitor of Kv1.5 and Kv1.3 potassium channels (EC50 = 3.1 μM) with notable immunomodulatory and anti-inflammatory properties. It effectively reduces Kv1.3 current density, diminishes Ca2+ influx in calcium-depleted Jurkat cells, and inhibits IL-2 secretion in activated Jurkat cells. Additionally, DPO-1 obstructs uric acid sodium (MSU)-induced NLRP3 inflammasome activation by interfering with Kv1.5-mediated K+ efflux. This reagent is valuable for research into immunological disorders and atrial fibrillation. -
NLRP3 Inhibitor
JT002 is a selective inhibitor of the NLRP3 inflammasome assembly. It effectively reduces the production of NLRP3-dependent proinflammatory cytokines, including IL-1β, IL-1α, and IL-18, while also inhibiting pyroptosis. In preclinical studies, JT002 demonstrated the ability to mitigate airway hyperresponsiveness and airway neutrophilia in murine models, making it a valuable tool for investigating various inflammatory diseases, such as Muckle-Wells syndrome. -
NLRP3 Inhibitor
NLRP3-IN-13 is a selective and potent inhibitor of the NLRP3 inflammasome, exhibiting an IC50 value of 2.1 μM. This compound effectively inhibits both NLRP3 and NLRC4 inflammasome activity, as well as NLRP3-mediated interleukin-1 beta (IL-1β) production. Additionally, NLRP3-IN-13 disrupts NLRP3 ATPase activity, making it a valuable tool for investigating neuroinflammatory disorders and related pathways. -
NLRP3 Inhibitor
JC124 is a selective inhibitor of the NLRP3 inflammasome, a crucial component in the inflammatory response. It demonstrates significant anti-inflammatory activities and provides neuroprotective effects, making it a valuable tool in research aimed at understanding neuroinflammation and related disorders. JC124 is suitable for studies investigating the modulation of inflammatory pathways and potential therapeutic interventions in various neurological conditions. -
NLRP3 Inhibitor
INF 195 is a potent NLRP3 inhibitor that effectively suppresses NLRP3-driven macrophage pyroptosis and interleukin-1 beta (IL-1β) release, exhibiting an EC50 value of 0.15 μM. This compound has demonstrated the ability to reduce infarct size in isolated mouse hearts at low doses, thereby providing protection against myocardial ischemia/reperfusion injury. INF 195 serves as a valuable tool for research focused on inflammation and cardiovascular diseases. -
NF-κB Inhibitor
Ergolide is a selective NF-κB/p65 and NLRP3 inhibitor that effectively disrupts the NF-κB signaling pathway and inhibits the nuclear translocation of p65. By irreversibly binding to the NACHT domain of NLRP3, Ergolie suppresses inflammasome assembly, significantly reducing the production of inflammatory mediators such as NO and PGE2. This compound promotes apoptosis in cancer cells, induces autophagy, and generates reactive oxygen species (ROS). Ergolide also enhances the therapeutic efficacy of vincristine and has been shown to alleviate acute lung injury in models of sepsis and inflammation, contributing to research in metastatic uveal melanoma, neurodegenerative diseases, and acute lymphoblastic leukemia. -
NLRP3 Inhibitor
Emlenoflast (MCC7840) is a potent and selective inhibitor of the NLRP3 inflammasome, exhibiting an IC50 of less than 100 nM. This sulfonylurea compound plays a critical role in modulating inflammatory responses and is valuable for research into various inflammatory diseases. Its ability to inhibit the NLRP3 pathway makes it a significant tool for investigating mechanisms of inflammation and developing therapeutic strategies. -
NLRP3 Selective Agonist
2-Guanidinobezimidazole is a selective agonist of the NLRP3 inflammasome, exhibiting a KD value of 1.29 μM towards His-GFP-NLRP3. By binding directly to the leucine-rich repeat (LRR) domain of NLRP3, it facilitates inflammasome assembly and activation. This compound is pertinent for research into anti-tumor immunity, demonstrating potential to inhibit tumor growth and address resistance to immune checkpoint blockade (ICB). -
NLRP3 Antagonist
NLRP3 Antagonist 1 is a selective antagonist of the NLRP3 inflammasome, primarily expressed in macrophages and neutrophils. This compound plays a crucial role in modulating the innate immune response to pathogenic infections and cellular stress. NLRP3 Antagonist 1 has potential applications in cancer research and other inflammatory diseases, providing a valuable tool for studying the underlying mechanisms of NLRP3-mediated pathways. -
COX-2 Inhibitor
Thymohydroquinone is a selective inhibitor of cyclooxygenase-2 (COX-2) with noted anti-SARS-CoV-2 activity. It exhibits cytotoxic properties, antiproliferative effects, and the ability to suppress tumor growth in various cancer models. This compound is applicable in research focused on squamous cell carcinoma, fibrosarcoma, and the pathogenesis and treatment of COVID-19 caused by SARS-CoV-2. -
HPV Epitope Peptides Fragment
Human Papillomavirus (HPV) E7 protein (49-57) is a fragment of the E7 protein, specifically the epitope spanning amino acid residues 49 to 57, which is restricted by the H-2d MHC class I molecule. This peptide is vital for studying HPV-induced tumorigenesis and immune response mechanisms. It is commonly utilized in research applications focusing on HPV vaccination, T cell recognition, and the understanding of viral oncogenesis. -
Antiviral/Anti-Inflammatory Glycoprotein
Lactoferrin from Bovine Milk is a multifunctional iron-binding glycoprotein that exhibits antiviral and anti-inflammatory properties. Released by neutrophils, it plays a crucial role in inhibiting microbial and viral adhesion, as well as entry into host cells. This compound is also known to prevent cell adhesion and growth, contributing to its potential anti-cancer and immunomodulatory effects. Lactoferrin is widely applied in research focused on immune response modulation and pathogen resistance. -
Anti-inflammatory Agent
Astin C is a cyclopeptide derived from Aster tataricus that acts as an anti-inflammatory agent. It specifically inhibits the cGAS-STING signaling pathway, preventing the recruitment of IRF3 to the STING signalosome, thereby modulating the innate inflammatory response. Astin C is valuable for research into autoimmune diseases and cancer, making it a key reagent for studying inflammation-related mechanisms. -
iNOS Inhibitor
S-Methylisothiourea sulfate serves as a potent, selective, and competitive inhibitor of inducible nitric oxide synthase (iNOS). This compound has demonstrated significant biological activity in reducing nitric oxide production and exhibits protective effects in rodent models of septic shock. Its role in modulating iNOS activity makes it a valuable reagent for research focused on inflammation and immune response mechanisms. -
Anti-inflammatory/Antiinfection Agent
Forsyshiyanine A is a triterpenoid alkaloid known for its anti-inflammatory and antiviral properties. It effectively inhibits the release of β-glucuronidase from rat polymorphonuclear leukocytes, thereby demonstrating notable anti-inflammatory activity. Forsyshiyanine A also exhibits antiviral efficacy, with an EC50 of 4.5 μM against respiratory syncytial virus (RSV) and an IC50 of 7.3 μM against influenza A virus (H1N1), reducing viral load through disruption of viral replication and entry. This compound is valuable for research in the fields of inflammation and infection. -
Bioactive Peptide
Influenza NP (311-325) is a bioactive peptide derived from the nucleoprotein (NP) of the influenza virus, acting as an MHC class II restricted epitope to stimulate host immune responses. This peptide is known for its ability to induce substantial interferon gamma (IFN-γ) production while avoiding activation of CD8 T cells in murine models. Its unique properties make Influenza NP (311-325) a valuable tool for research in immunology and vaccine development. -
Anti-Inflammatory Agent
Agathisflavone is a flavonoid compound primarily recognized for its anti-inflammatory properties. It exhibits a range of biological activities, including antioxidant, antiviral, antiparasitic, cytotoxic, neuroprotective, and hepatoprotective effects. Research indicates that Agathisflavone may enhance tissue repair processes, particularly in spinal cord injury models in rodents, making it a valuable reagent for studies in inflammation and regenerative medicine. -
Nonimmunosuppressive Cyclophilin Inhibitor
NIM258 is a potent nonimmunosuppressive cyclophilin inhibitor, specifically targeting cyclophilin A with a Kd of 1.2 nM. It exhibits significant anti-HCV activity, with an EC50 of 40 nM. This compound serves as a valuable tool for research into HCV infection and its associated pathways. -
CXCR4 Antagonist
Mavorixafor trihydrochloride is a potent and selective antagonist of the CXCR4 receptor, exhibiting an IC50 of 13 nM in inhibiting CXCR4 125I-SDF binding. This compound has demonstrated significant antiviral activity by inhibiting the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs, with IC50 values of 1 nM and 9 nM, respectively. Mavorixafor trihydrochloride is applicable in research studying WHIM syndrome and various CXCR4-related biological processes. -
CCR7 and CXCR2 Antagonist
Cosalane is a dual antagonist of the chemokine receptors CCR7 (IC50 = 2.43 μM) and CXCR2 (IC50 = 0.66 μM). This compound effectively inhibits HIV replication across a variety of strains, including HIV-1, HIV-2, Rauscher murine leukemia virus, as well as herpes simplex viruses HSV-1 and HSV-2, and human cytomegalovirus. Cosalane disrupts the interaction between gp120 and CD4, inhibiting signaling downstream of CCR7 in response to its ligands CCL19 and CCL21. Research applications include studies on HIV and the potential modulation of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. -
CCR5 Inhibitor
DAPTA is a synthetic peptide that acts as a selective inhibitor of the CCR5 receptor. By blocking CCR5, DAPTA interferes with viral entry into host cells, exhibiting significant anti-HIV activity. This compound is valuable for research in virology and the development of therapeutic strategies against HIV. -
CXCR4 Antagonist
TC14012 is a peptidomimetic antagonist targeting the chemokine receptor CXCR4, exhibiting a high level of selectivity with an IC50 of 19.3 nM. In addition, TC14012 acts as a potent agonist for CXCR7, demonstrating an EC50 of 350 nM in β-arrestin 2 recruitment assays. This compound is utilized in research focused on HIV and cancer therapy, showcasing its potential in modulating chemokine signaling pathways. -
CXCR4 Antagonist
FC131 TFA is a potent CXCR4 antagonist that effectively inhibits the binding of [125I]-SDF-1 to CXCR4, demonstrating an IC50 value of 4.5 nM. This compound exhibits significant anti-HIV activity, making it a valuable tool for research in HIV treatment and other CXCR4-related studies. Its ability to disrupt CXCR4 signaling can be explored in various biological contexts, including cancer metastasis and immune response regulation. -
CXCR4 Antagonist
AMD 3465 is a potent antagonist of the CXCR4 chemokine receptor. It effectively inhibits the binding of both the 12G5 monoclonal antibody and CXCL12AF647 to CXCR4, demonstrating IC50 values of 0.75 nM and 18 nM in SupT1 cells, respectively. Additionally, AMD 3465 significantly impedes the replication of X4-tropic HIV strains, with IC50 values ranging from 1 to 10 nM, while showing no activity against CCR5-using (R5) viruses. This compound is suitable for research applications focusing on HIV treatment and CXCR4-related signaling pathways. -
CCR5 Antagonist
Aplaviroc hydrochloride is a potent CCR5 antagonist targeting the CCR5 co-receptor. It demonstrates biological activity with IC50 values ranging from 0.1 to 0.4 nM against various HIV-1 strains, including HIV-1Ba-L, HIV-1JRFL, and HIV-1MOKW. This compound is valuable for research applications focused on HIV entry inhibition and the development of antiviral therapies. -
HIV-1 Nef Binder, IKZF1 Modulator
FC-14369 is a PROTAC degrader that selectively targets the HIV-1 Nef protein, exhibiting a DC50 value of 160 nM. By engaging both Nef and the Cereblon E3 ubiquitin ligase, FC-14369 facilitates the ubiquitination and subsequent proteasomal degradation of Nef, leading to the restoration of CD4 and MHC-I expression on the cell surface and effectively inhibiting HIV-1 replication. This compound is valuable for research focused on HIV infection and AIDS, advancing understanding of therapeutic strategies in viral infections. -
CXCR4 Antagonist
KRH-3955 hydrochloride is a potent CXCR4 antagonist that effectively inhibits the binding of SDF-1α to CXCR4 with an IC50 of 0.61 nM. This compound demonstrates strong selectivity and efficacy against X4 HIV-1, with an EC50 ranging from 0.3 to 1.0 nM. KRH-3955 hydrochloride is suitable for research applications focused on HIV-1 pathogenesis and CXCR4-related signaling pathways. -
CXCR4 Antagonist
FC131 is a potent antagonist of the CXCR4 chemokine receptor. It effectively inhibits the binding of [125I]-SDF-1 to CXCR4 with an IC50 value of 4.5 nM. Due to its mechanism of action, FC131 demonstrates significant anti-HIV activity, making it a valuable tool for research into HIV pathogenesis and potential therapeutic interventions. -
Stable Isotope
Plerixafor-d4 is a deuterated derivative of Plerixafor, a selective antagonist of the CXCR4 receptor with an IC50 of 44 nM. This compound serves as an immunostimulant and is known for its ability to mobilize hematopoietic stem cells (HSCs). Additionally, Plerixafor has demonstrated efficacy in inhibiting HIV-1 and HIV-2 replication, with an EC50 ranging from 1 to 10 nM. Plerixafor-d4 is useful in research applications requiring stable isotopes for tracking and quantification purposes. -
HIV-1 Entry Inhibitor
RPR103611 is a derivative of betulinic acid that functions as a potent HIV-1 entry inhibitor. It displays IC50 values of 80 nM for CCR5-tropic virus YU2, 0.27 nM for CXCR4-tropic virus NL4-3, and 0.17 nM for dual tropic virus 89.6. This compound is valuable for research focused on the mechanisms of HIV-1 entry and the development of antiviral therapies. -
CCR5 Antagonist
CCR5 antagonist 3 is a potent inhibitor of the CCR5 receptor, exhibiting an IC50 of 15.90 nM. This compound demonstrates broad-spectrum anti-HIV-1 activity, making it a valuable tool for research focused on HIV-1 infection mechanisms and therapeutic development. Its specificity for CCR5 enhances its potential utility in studying chemokine receptor modulation and viral entry inhibition in various biological contexts. -
CCR5 Antagonist
Ancriviroc is a small molecule CCR5 antagonist that demonstrates potent antiviral activity against various HIV-1 isolates that utilize CCR5 as an entry coreceptor, with IC50 values ranging from 0.4 to 9 nM. This compound effectively inhibits the replication of R5-utilizing HIV-1 strains in the SCID-hu Thy/Liv mice model of HIV-1 infection. Ancriviroc is a valuable tool for research focused on HIV infection and the exploration of therapeutic strategies targeting CCR5. -
CXCR4 Antagonist
CXCR4 antagonist 7 is a potent CXCR4 antagonist with an IC50 of 9.3 nM. It effectively inhibits CXCR4 receptor activity, making it a valuable tool in the investigation of HIV infection, inflammatory diseases, cancer, and WHIM syndrome. This compound provides essential insights into the roles of CXCR4 signaling in various pathological conditions. -
CCR5 Antagonist
INCB9471 is a potent and selective CCR5 antagonist that serves as a critical resource for HIV-1 research. This orally active compound effectively inhibits CCR5-mediated entry of HIV-1 into host cells, demonstrating significant anti-HIV-1 activity. Its targeted mechanism of action makes INCB9471 a valuable tool for studying HIV pathogenesis and developing therapeutic strategies against HIV infection. -
CCR5 Antagonist
Vicriviroc is a potent CCR5 antagonist with an IC50 of 10 nM. It effectively inhibits the release of MIP-1α and intracellular calcium levels induced by the ligand RANTES, with IC50 values of 0.91 nM and 16 nM, respectively. Vicriviroc is primarily utilized in research related to human immunodeficiency virus type 1 (HIV-1) infection and holds potential for cancer studies. -
CXCR Inhibitor
AMD 3329 octahydrobromide is a potent CXCR4 inhibitor that effectively reduces HIV-1 and HIV-2 viral replication. It demonstrates exceptional antiviral activity with EC50 values of 0.8 nM and 1.6 nM, surpassing the efficacy of related compounds. Additionally, AMD 3329 significantly obstructs the binding of specific CXCR4 monoclonal antibodies and inhibits SDF-1 alpha-induced Ca(2+) influx. This compound also disrupts virus-induced syncytium formation, with an EC50 of 12 nM, making it a valuable tool for HIV research and therapeutic development. -
NRF2 Activator
BC-1901S is a proteasome-independent activator and stabilizer of NRF2. It functions by binding to DCAF1, an E3 ligase subunit, disrupting the NRF2/DCAF1 interaction, and inhibiting NRF2 ubiquitination through a KEAP1-independent pathway. BC-1901S demonstrates anti-inflammatory effects in murine models of LPS-induced acute lung injury, making it a valuable tool for research into NRF2-related pathways and inflammation. -
IKZF Degrader
BMS-986482 is a CRBN-mediated IKZF degrader that selectively targets the IKZF1-4 protein family. Its unique CELMoD™ core facilitates the degradation of these proteins, leading to impaired tumor growth as demonstrated in preclinical mouse models. This compound is particularly valuable for research focused on advanced solid tumors, providing insights into therapeutic strategies that disrupt IKZF protein function. -
Anti-Inflammatory Agent
Comanthoside B is a flavonoid glycoside derived from the aerial parts of Ruellia tuberosa L. It exhibits significant anti-inflammatory and antiseptic properties, making it a valuable reagent for studies focused on inflammation-related pathways. Its biological activity supports its use in exploring therapeutic strategies for inflammatory conditions. -
Anti-inflammatory agent
Hentriacontane is a long-chain alkane that acts as an anti-inflammatory agent by inhibiting the NF-κB signaling pathway. Its bioactivity encompasses not only anti-inflammatory effects but also antitumor and antibacterial properties. This compound is valuable for research applications focused on inflammation modulation, cancer biology, and antimicrobial studies. -
Nonsteroidal Anti-inflammatory Agent
Oxyphenbutazone monohydrate is a nonsteroidal anti-inflammatory agent that functions as a non-selective inhibitor of cyclooxygenase (COX). It exhibits significant anti-inflammatory properties, making it a valuable reagent in pharmacological research. Additionally, Oxyphenbutazone monohydrate has been shown to selectively target and eliminate non-replicating Mycobacterium tuberculosis, highlighting its potential in tuberculosis research and therapy development. -
Anti-inflammatory Agent
5'-Methoxynobiletin is a polymethoxyflavone that acts as a potent anti-inflammatory agent. Isolated from A. conyzoides, this compound exhibits significant antinociceptive properties, making it valuable for research focused on pain management and inflammation. Its efficacy in modulating inflammatory pathways positions it as an important tool for scientists investigating anti-inflammatory mechanisms and therapeutic applications. -
Anti-inflammatory compound
Batatasin I is an anti-inflammatory compound derived from the tuberous roots of Dioscorea batatas. This natural product exhibits notable antifungal activity and has been shown to modulate inflammatory processes. Batatasin I is applicable in research focused on inflammatory diseases and may serve as a lead compound for the development of new therapeutic agents in this area. -
Anti-inflammatory Agent
Methylarbutin functions as an anti-inflammatory agent, demonstrating significant anti-inflammatory properties. It has been shown to possess urinary antiseptic activity, making it a useful compound in research focused on inflammatory conditions and urinary tract health. Methylarbutin can be utilized in studies aimed at elucidating mechanisms involved in inflammation and infection. -
Anti-inflammatory/immunomodulator
Isozaluzanin C is a dehydrozaluzanin C derivative that acts as an anti-inflammatory agent and immunomodulator. Isolated from Saussurea lappa, it has demonstrated the ability to ameliorate tissue damage in various organs, including the lung, kidney, and liver, in murine models of LPS-induced or CRKP infection. This compound is valuable for research on bacterial infections and sepsis, providing insights into the mechanisms underlying inflammatory responses. -
iNOS Inhibitor
Myricadenin A is an inhibitor of inducible nitric oxide synthase (iNOS), demonstrating effective inhibition of nitric oxide production with an EC₅₀ value of 18.1 μM. Additionally, it exhibits moderate ABTS free radical scavenging activity (SC₅₀ = 175.4 μM) and shows weak antibacterial activity against tuberculosis (MIC = 80.0 μg/mL). Myricadenin A is suitable for studies focused on inflammation and oxidative stress. -
iNOS/COX-2 Inhibitor
Ermanin is a flavonoid extracted from Tanacetum microphyllum, known for its potent inhibitory effects on inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Its biological activities include anti-inflammatory, anti-tuberculous, and anti-viral/bacterial properties, making it a valuable reagent in research related to inflammation and infectious diseases. Ermanin is useful for exploring the pathways associated with nitric oxide production and prostaglandin synthesis in various biological contexts. -
LCMV Glycoprotein Peptides Frgment
LCMV gp33-41 is a peptide fragment derived from the glycoprotein of the lymphocytic choriomeningitis virus (LCMV), specifically a carboxyl-extended 9-amino acid sequence. This peptide is restricted by MHC class I H-2Db molecules, facilitating its recognition and presentation to cytotoxic T lymphocytes. LCMV gp33-41 is pivotal for immunological research applications, including the study of T cell responses and viral pathogenesis. -
STING Agonist
c-di-AMP disodium is a cyclic dinucleotide serving as a STING agonist, which interacts with the STING protein to activate the TBK1-IRF3 signaling pathway. This activation leads to the production of type I interferons and tumor necrosis factor, playing a pivotal role in the immune response. In addition to its function in immune modulation, c-di-AMP is a bacterial second messenger that regulates various physiological processes in Gram-positive bacteria, including growth and virulence. Its properties also make it an effective mucosal adjuvant for enhancing both humoral and cellular immune responses in research applications. -
Exotoxin
LLO (91-99), a peptide derived from the exotoxin listeriolysin O, acts as a class I MHC-restricted T-cell epitope. This peptide is processed by antigen-presenting cells, binding to MHC class I molecules to elicit cytotoxic T lymphocyte (CTL) responses. LLO (91-99) is instrumental in research focused on Listeria infections, such as listeriosis, by facilitating the clearance of Listeria from infected cells.
